scholarly journals Liquid biopsy and therapeutic response: Circulating tumor cell cultures for evaluation of anticancer treatment

2016 ◽  
Vol 2 (7) ◽  
pp. e1600274 ◽  
Author(s):  
Bee Luan Khoo ◽  
Gianluca Grenci ◽  
Tengyang Jing ◽  
Ying Bena Lim ◽  
Soo Chin Lee ◽  
...  
Keyword(s):  
Tumor Cell ◽  
Drug Screening ◽  
Liquid Biopsy ◽  
Early Stage ◽  
Drug Evaluation ◽  
Cluster Formation ◽  
Locally Advanced ◽  
Metastatic Breast ◽  
Circulating Tumor Cell ◽  
Personalized Treatment

The lack of a robust anticancer drug screening system to monitor patients during treatment delays realization of personalized treatment. We demonstrate an efficient approach to evaluate drug response using patient-derived circulating tumor cell (CTC) cultures obtained from liquid biopsy. Custom microfabricated tapered microwells were integrated with microfluidics to allow robust formation of CTC clusters without pre-enrichment and subsequent drug screening in situ. Rapid feedback after 2 weeks promotes immediate intervention upon detection of drug resistance or tolerance. The procedure was clinically validated with blood samples (n = 73) from 55 patients with early-stage, newly diagnosed, locally advanced, or refractory metastatic breast cancer. Twenty-four of these samples were used for drug evaluation. Cluster formation potential correlated inversely with increased drug concentration and therapeutic treatment. This new and robust liquid biopsy technique can potentially evaluate patient prognosis with CTC clusters during treatment and provide a noninvasive and inexpensive assessment that can guide drug discovery development or therapeutic choices for personalized treatment.

Circulating tumor cell status and benefit of radiotherapy in stage I breast cancer.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 11524-11524
Author(s):  
Chelain Rae Goodman ◽  
Brandon-Luke L Seagle ◽  
Eric Donald Donnelly ◽  
Jonathan Blake Strauss ◽  
Shohreh Shahabi
Keyword(s):  
Breast Cancer ◽  
Tumor Cell ◽  
Proportional Hazards ◽  
Early Stage ◽  
Cohort Analysis ◽  
Metastatic Breast ◽  
Circulating Tumor Cell ◽  
Cox Proportional Hazards ◽  
Stage I ◽  
Matched Cohort

11524 Background: Circulating tumor cell (CTC) status has been shown to be prognostic of decreased survival in non-metastatic breast cancer. While up to 20-30% of patients with early breast cancer have detectable CTCs, less is known regarding the role of CTC-status in guiding clinical management. Methods: An observational cohort study was performed on women with stage I breast cancer evaluated for CTCs from the 2004-2014 National Cancer Database. Logistic regression was used to explore clinicopathological associations with CTC-status. Kaplan-Meier and multivariable Cox proportional-hazards survival analyses were used to estimate associations of CTC-status with overall survival using a propensity score-adjusted and inverse probability-weighted matched cohort. Results: Of the stage I breast cancer women evaluated for CTCs, 23.1% (325/1,407) were CTC-positive. Age, histology, receptor status, and nodal stage were associated with CTC-status. CTC-status was an effect modifier of the radiotherapy-survival association: CTC-positive women who did not receive radiotherapy had an increased hazard of death compared to CTC-negative women who also did not receive radiotherapy (four-year survival: 85.7% vs. 93.3%, HR = 2.92, CI = 1.43-5.98, P = 0.003). CTC-positive patients treated with radiotherapy did not have decreased survival compared to CTC-negative patients not treated with radiotherapy (HR = 0.67, CI = 0.28-1.65, P = 0.40). From the matched cohort analysis, CTC-positive women who did not receive radiation had a 4.82-fold increased hazard of death compared to CTC-positive women treated with radiotherapy (four-year survival: 83.2% vs. 96.6%; CI = 2.62-8.85, P < 0.001). Conclusions: Treatment with adjuvant radiotherapy was associated with improved survival in CTC-positive women with stage I breast cancer. If prospectively validated, CTC-status may be valuable as a predictor of benefit of radiotherapy in early stage breast cancer.

scholarly journals Antibody-modified reduced graphene oxide film for circulating tumor cell detection in early-stage prostate cancer patients

RSC Advances ◽  
2019 ◽  
Vol 9 (17) ◽  
pp. 9379-9385 ◽  
Author(s):  
Binshuai Wang ◽  
Yimeng Song ◽  
Liyuan Ge ◽  
Shudong Zhang ◽  
Lulin Ma
Keyword(s):  
Prostate Cancer ◽  
Graphene Oxide ◽  
Oxide Film ◽  
Tumor Cell ◽  
Cancer Patients ◽  
Reduced Graphene Oxide ◽  
Early Stage ◽  
Circulating Tumor Cell ◽  
Cell Detection ◽  
Reduced Graphene

We report the fabrication of an antibody-modified reduced graphene oxide film, which can be used to efficiently detect CTCs in PCa patients with PSA levels of 4–10 ng mL−1.

Early Detection of Cancer Using Smartphones

2021 ◽  
pp. 25-31
Author(s):  
Kodieswari A.
Keyword(s):  
Early Detection ◽  
Tumor Cell ◽  
Cancer Cells ◽  
Cancer Cell ◽  
Early Detection Of Cancer ◽  
Early Stage ◽  
Circulating Tumor Cell ◽  
Efficient Technology ◽  
Abnormal Growth ◽  
High Death

Cancer disease is the second largest disease in the world with high death mortality. Cancer is an abnormal growth of a normal cell. There are more than 100 types of cancer like blood cancer, brain cancer, small intestine cancer, lung cancer, liver cancer, etc. The type of cancer can be classified by the type of cell which is initially affected. When cancer grows it does not show any symptom. The symptom will appear when the cancer cell grows in mass and the symptom of cancer depends on the type of cancer. The cause of cancers is environmental pollutants, food habits, inherited genetics, tobacco, stress, etc., but in practice, it is not possible to prove the cause of cancer since various cancers do not have specific fingerprints. After the heart attack, cancer is a second killer disease in India. The death mortality is high in cancer because in most of the cases it is identified at the final stage which causes more death. According to ICMR, among 1.27 billion Indian populations, the incidence of cancer is 70-90 per 100,000 populations and 70% of cancer is identified in the last stage accounting for high morality. There are many types of treatment to treat cancer and they are surgery, radiation therapy, chemotherapy, targeted therapy, hormone therapy, stem cell transplant, etc. All cancer treatments will have side effects and the treatments will help only if the cancer cells are identified at the early stage. So time factor is important in diagnosing of cancer cells; hence, early detection of cancer will reduce the mortality rate. This chapter proposed the early detection of cancer cells using image processing techniques by the structure of circulating tumor cell. Early detection of cancer cells is very difficult because the concentration of cancer cells are extremely small and about one million malignant cell is encountered per billion of healthy cells. The circulating tumor cells, CTC, are shed into the bloodstream as a tumor grows, and it is believed these cells initiate the spread of cancer. CTC are rare, existing as only a few per one billion blood cells, and a highly efficient technology like chip-based biosensor platforms is required to capture the CTC, which in turn helps to detect cancer cell at an early stage before spreading. In proposed method, the circulating tumor cell has used a marker to detect cancer at early stage.

Sign in / Sign up

Export Citation Format

Share Document